LU505877B1 - Bacillus-based product having virucide activity against enveloped virus and applications thereof - Google Patents
Bacillus-based product having virucide activity against enveloped virus and applications thereof Download PDFInfo
- Publication number
- LU505877B1 LU505877B1 LU505877A LU505877A LU505877B1 LU 505877 B1 LU505877 B1 LU 505877B1 LU 505877 A LU505877 A LU 505877A LU 505877 A LU505877 A LU 505877A LU 505877 B1 LU505877 B1 LU 505877B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- strains
- bacillus
- strain
- bccm
- december
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
- A01N63/22—Bacillus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/381—Microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pest Control & Pesticides (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Dentistry (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Agronomy & Crop Science (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention relates to new isolated strains of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, to a bacterial preparation comprising at least one of these strains, to their uses, in particular as active ingredient in a probiotic-based product having a virucidal activity against enveloped viruses, and to a process for cleaning and/or preventing from contamination and/or sanitizing a surface using at least one of these strains.
Description
BACILLUS-BASED PRODUCT HAVING VIRUCIDE ACTIVITY AGAINST 0505877
ENVELOPED VIRUS AND APPLICATIONS THEREOF
The invention belongs to the field of probiotic products.
In particular, the invention relates to five new isolated strains of spore- forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, to a bacterial preparation comprising at least one of these five strains of spore-forming bacteria of the Bacillus species, to their uses, in particular as active ingredient in a probiotic-based product having a virucidal activity against enveloped viruses, and to a process for cleaning and/or preventing from contamination and/or sanitizing a surface using at least one of these five strains.
The detergent industry today faces a constant challenge to meet the requirements and standards relating to cleanliness and hygiene.
Current surface cleaning and disinfection products have shown their limits, particularly in the fight against the recontamination of surfaces by pathogens. In fact, the products traditionally used for surface disinfection only have a transient effect since they only ensure the elimination of pathogens already in place without preventing rapid recontamination of surfaces by pathogenic agents.
In addition, traditional disinfectant products have the disadvantage of being dangerous products (irritant, corrosive risk, etc.) containing molecules toxic to humans and the environment (chlorinated products, quaternary ammoniums, glutaraldehyde, etc.). In addition, these products are difficult to biodegrade.
Furthermore, the chemical agents contained in these disinfection products can react with other molecules used in cleaning, which results in an inhibition of their disinfectant activity and potentially an additional toxic risk for users.
Another disadvantage of using traditional chemical-based disinfectant compositions is the fact that they require a long contact time with the surface to be cleaned, up to 15 minutes. Thus, their effectiveness is compromised if this time is not respected.
In practice, legislation is increasingly strict regarding the use of these LU505877 disinfection products. There is therefore a growing demand from cleaning professionals and consumers to use products that are effective, but safer for humans and the environment.
In this context, alternative solutions have been sought.
Thus, cleaning products use a so-called “bio-control” approach, based on competitive antagonism between probiotic (non-pathogenic) microorganisms present in the product which colonize surfaces and other potentially pathogenic bacterial species.
There are products on the market used for cleaning and sanitizing surfaces in which spores of bacteria of the genus Bacillus are associated with a detergent formulation. As examples, one can mention the range of products PROBISANA ® sold by Chrisal N.V and the product PROBIO MULTI ® sold by Greenspeed, both containing a selection of natural probiotics as active ingredients.
International application WO 2016/170479 describes a product for cleaning, sanification and hygienization of surfaces or ambiants comprising a combination of non-ionic, cationic and amphoteric surfactant, in association with probiotic bacteria spores of the Bacillus genus (B. subtilis, B. megaterium and B. pumilis species) and selected bacteriophages.
International application WO2021/243324 discloses an aqueous microbial cleaning composition comprising bacterial spores and a surfactant selected among polyalkylglucosides and sodium lauryl ether sulfates.
The detergent-based products on the marked or described in these prior art documents use a “bio-control” approach based on the fact that the probiotic (no pathogenic) microorganisms present therein can colonize the surfaces after said surfaces have been cleaned by the action of surfactants, thus competing with proliferation of other species potentially dangerous for people health.
However, the drawbacks of these products are that they involve the use of surfactants that have a non-negligible impact on the environment and that the microorganisms they comprise do not have an intrinsic virucidal activity.
With the recent appearance of pandemic caused by coronavirus (such as
SARS-CoV-2), and more generally to fight against contaminations by enveloped viruses, there is a need for a probiotic product that, in addition to bactericide and LU505877 cleaning properties, has also a virucidal activity against enveloped viruses.
OBJECTS AND SUMMARY
An object of the present invention is therefore to provide probiotic product that can be used to clean, and/or preventing from contamination and/or sanitizing surfaces without any human, animal and environmental toxicity.
The Applicants have isolated five new strains of spore-forming bacteria of the Bacillus species that have a virucidal activity against enveloped viruses.
A first object of the present invention are isolated strains of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said strains are selected from Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian Coordinated Collections of
Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P-33408 at the BCCM on
December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P- 33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on December 8, 2023.
A second object of the present invention is a bacterial preparation comprising at least one strain of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said at least one strain is selected in the group consisting of the five following strains: Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian
Coordinated Collections of Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on
December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P- 33408 at the BCCM on December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P-33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on
December 8, 2023
A third object of the present invention is the use of at least one of these five strains as defined according to the first object of the present invention, as active ingredient in a probiotic-based non therapeutical product having a virucidal LU505877 activity against enveloped viruses.
A fourth object of the present invention is the use of a bacterial preparation according to the second object of the present invention, as active ingredient in a probiotic-based non therapeutical product having a virucidal activity against enveloped viruses.
A fifth object of the present invention is a process for cleaning and/or preventing from contamination and/or sanitizing a surface, said process comprising at least one step of applying on said surface, at least one strain as defined according to the first object of the present invention or at least one bacterial preparation according to the second object of the present invention.
A sixth object of the present invention is the strains as defined according to the first object of the present invention, for use as a medicament.
A seventh object of the present invention is the bacterial preparation as defined according to the second object of the present invention, for use as a medicament.
The definitions below correspond to the meaning generally used in the context of the invention and are to be taken into account, unless another definition is explicitly indicated.
The terms “about”, used in reference to a measurable value such as a quantity, a duration, and other similar values, must be understood as encompassing measurement uncertainties of + 20% or + 10%, preferably + 5%, even more preferably £ 1% of the specified value.
The term “isolated” must be understood in the context of the invention as a synonym for removed or extracted from its environment or natural state. For example, a strain of isolated bacteria is a strain of bacteria extracted from the natural environment in which it is usually found, whether it is a surface or animal for example. Thus, a strain of bacteria naturally present on a surface or in a living animal is not a strain of bacteria within the meaning of the invention, while the same strain of bacteria, partially or completely separated from the others elements present in its natural context, is for its part “isolated” within the meaning of the LU505877 invention.
In the context of the invention, the following abbreviations are used for the most common nucleic acid bases. “A” refers to adenosine, "C” refers to 5 cytosine, “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.
The terms "homologous", "identical" and “identity” refer to sequence similarity or sequence identity between two nucleic acid molecules. When a position in each of the two compared sequences is occupied by the same base (for example, when a position in each of the two DNA molecules is occupied by an adenine), then the molecules are homologous or identical for this position. The percentage of identity between two sequences is a function of the number of corresponding positions shared by the two sequences, and corresponds to this number divided by the number of positions compared and multiplied by 100. For example, if 6 out of 10 of the positions in two matched sequences are identical, then the two sequences are 60% identical. Typically, the comparison is performed by aligning the two sequences to give maximum homology/identity.
As already stated the Applicants have identified new microorganism, in this case five new strains of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses. To the Applicant's knowledge, these are the first strains of the bacillus species having a virucidal activity against enveloped viruses in addition to antagonist activity against several families of bacterial known to be pathogens likely to be present on surfaces to be cleaned.
Thus, according to a first object, the invention relates to isolated strains of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said strains are selected from Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian Coordinated Collections of Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P-33408 at the BCCM on
December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P- 33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on December 8, 2023.
According to a particular embodiment of the present invention, said strains LU505877 have a consensus nucleotidic sequence SEQ ID N°1 or a nucleotidic sequence having at least 95% of identity, preferably at least 96%, 97%, 98%, 99%, or even 99.5%, or even 99.9% of identity with said nucleotidic sequence SEQ ID N°1.
SEQ ID N°1 corresponds to the common partial sequence of the genes that share at least 95% of identity with the five strains according to the invention.
Advantageously, the strain Bacillus altitudinis, deposited under the number
LMG P-33406 (strain P9) has the sequences SEQ ID N°2 to SEQ ID N° 9 or sequences having at least 95%, advantageously at least 96%, 97%, 98%, 99% or even 99.5% or even 99.9% identity with these sequences.
Advantageously, the strain Bacillus subtilis, deposited under the number
LMG P-33407 (strain P13) has the sequences SEQ ID N°10 to SEQ ID N°12 or sequences having at least 95%, advantageously at least 96%, 97%, 98%, 99% or even 99.5% or even 99.9% identity with these sequences.
Advantageously, the strain Bacillus safensis, deposited under the number
LMG P-33408 (strain P14) has the sequences SEQ ID N°13 to SEQ ID N°17 or sequences having at least 95%, advantageously at least 96%, 97%, 98%, 99% or even 99.5% or even 99.9% identity with these sequences.
Advantageously, the strain Bacillus nakamurai, deposited under the number LMG P-33409 (strain P17) has the sequences SEQ ID N°18 to SEQ ID N°90 or sequences having at least 95%, advantageously at least 96%, 97%, 98%, 99% or even 99.5% or even 99.9% identity with these sequences.
Advantageously, the strain Bacillus pumilus, deposited under the number
LMG P-33410 (strain P18) has the sequence SEQ ID N°91 or sequences having at least 95%, advantageously at least 96%, 97%, 98%, 99% or even 99.5% or even 99.9% identity with these sequences.
In according with the belonging of the strains of the invention to the
Bacillus species, these are advantageously capable of growing in anaerobic and/or aerobic conditions, on classic rich media containing peptones and hydrolysates of animal or plant proteins, yeast extracts and salt, or on specific media or culture of
Bacillus type strains well known to those skilled in the art.
As already mentioned, the strains according to the invention are capable LU505877 of sporulating or forming spores, for example after cultivation in a medium promoting sporulation such as Difco Sporulation Medium (DSM).
An essential characteristic of the strains of the invention lies in their virucidal activity against enveloped-viruses, individually or in admixture.
Another characteristic of the strains of the invention lied in their antagonistic activity against surface pathogens.
In the context of the invention, the terms “antagonistic activity”, “antagonism” or “antagonistic power” have an equivalent meaning. They target the ability of the strains to reduce or even inhibit the growth and/or activity of different microorganisms, advantageously a surface pathogen.
This action can be carried out by production and secretion of inhibitory molecules (bacteriocins, antibiotics, toxins, etc.) and/or by competition.
By “competition”, it is meant a competitive relationship between microorganisms when they depend on the use of the same resource (nutrients) and/or the same territory/space, thus reducing the availability of nutrients and/or space for each of the competitors, without there necessarily being a direct interaction between the competing microorganisms. In practice, the strains according to the invention will occupy the field by consuming the organic materials which will accumulate after cleaning and/or produce antagonistic molecules which will prevent "bad" bacteria from settling in, thus ensuring a long-term effect.
Surface pathogens are microorganisms in particular bacteria, advantageously belonging to the following families: Staphylococcaceae,
Enterococcaceae, Enterobacteriaceae and Pseudomonadaceae.
Advantageously, the strains according to the invention exhibits antagonistic activity towards pathogenic bacteria of the following bacterial genus:
Staphylococcus, Enterococcus, Escherichia and Pseudomonas.
According to a particular embodiment, the target pathogens are
Staphylococcus aureus, Enterococcus hirae, Escherichia coli and Pseudomonas aeruginosa.
The antagonistic activity of a microorganism, in particular of strains LU505877 according to the invention, can be demonstrated by different techniques known to those skilled in the art, in particular by a viability qPCR test.
Finally, thanks to their enzymatic activities, the strains according to the invention are able to metabolize different substrates such as lipids, proteins, polysaccharides, etc., allowing their use of the cleaning of carious dirt on various surfaces.
A second object of the present invention is a bacterial preparation comprising a culture of at least one strain of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said at least one strain is selected in the group consisting of the five following strains: Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian
Coordinated Collections of Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on
December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P- 33408 at the BCCM on December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P-33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on
December 8, 2023.
According to a particular and preferred embodiment of the present invention, said bacterial preparation is free from any surface-active agent (or surfactant). Indeed, and as it is demonstrated in the following illustrative examples, the strains according to the invention does not need to be used in combination with a surfactant to exhibit their virucidal and bactericidal activities.
The strains of the invention can be used individually or in admixture.
Therefore, according to an embodiment of the present invention, the bacterial preparation comprises a culture of at least one said five strains, at least two of said five strains, at least three of said five strains, at least four of said five strains or even more preferably said five strains.
In the bacterial preparation, said strains can be in the form of spores and/or of vegetative cells and/or of cells in the transitional sporulation phase.
According to a preferred embodiment of the invention, said strains are in LU505877 the form of spores and are suspended in an aqueous medium, preferably an aqueous medium.
An aqueous medium is defined as a medium in which water constitutes the majority solvent. Such an aqueous medium may also contain a smaller quantity of a solvent other than water, capable of evaporating after application of the bacterial preparation to the surface to be cleaned, thus promoting its drying, advantageously a vegetable solvent such as for example isopropanol or ethanol.
The bacterial preparation according to the invention may further comprise one or several additional ingredients except surfactants, such as a preservative, a perfume, a dye, a thickening agent, an enzyme, a sequestering agent, an abrasive, an acidity corrector, etc. On this occasion, however, the person skilled in the art will ensure that the addition of these additional ingredients does not alter the intrinsic properties of the bacterial preparation, and in particular, the virucidal properties of the strain or strains it contains.
According to a particular embodiment, the preservative present in a bacterial preparation according to the invention, making it possible to stabilize the preparation without damaging the at least one strain contained therein, can be for example sodium benzoate, potassium sorbate, isothiazolinone type molecules, propylene glycol, phenoxyethanol or their mixtures.
According to a particular embodiment, the sequestering agent used in a bacterial preparation according to the invention may be ethylene diamine tetraacetic acid (EDTA), sodium citrate or a mixture thereof.
According to a particular embodiment, the abrasive used in a bacterial preparation according to the invention may be calcium carbonate, magnesium carbonate or a mixture thereof.
According to another particular embodiment, the acidity corrector used in a bacterial preparation according to the invention may be lactic acid, malic acid, citric acid, sodium hydroxide or a mixture thereof.
According to another particular embodiment, a thickener such as xanthan or polyvinyl alcohol or any other stabilizing agent which prevents the redeposition of the bacterial strain can be added to the bacterial preparation according to the invention.
In the bacterial preparation of the invention, the concentration of said LU505877 strain(s) is preferably from about 102 to 102 CFU/ML, even more preferably from about 10% to 10*° CFU/ML.
Throughout the rest of the description, the abbreviation CFU stands for “colony forming unit”.
The terms “CFU” and “number of bacteria” can be used interchangeably.
According to a particular embodiment, the bacterial cells and/or spores, or even the extracellular extracts, present in the culture media can be used directly, concentrated or purified by conventional methods, such as centrifugation, filtration, or evaporation.
According to another embodiment, the bacterial preparation according to the invention comprises as the only microorganism, advantageously as the only probiotic strain, at least one of the five strains as defined according to the first object of the present invention.
In other words, a bacterial preparation according to the invention may not contain any other microorganisms, in particular no other bacteria.
According to an advantageous embodiment, a bacterial preparation according to the invention does not contain any other bacteria of the Bacillus species.
According to an alternative embodiment, said bacterial preparation comprises, in addition to the at least one strain according to the invention, at least one other microorganism, for example another probiotic strain. In particular, another probiotic strain may be a Bacillus type strain different from that of the invention advantageously presented in sporulated form. Among these additional strains, one can mention a strain of Bifidobacterium, Carnobacterium,
Corynebacterium, Gluconobacter, Lactococcus, Lactobacillus (L.), Leuconostoc,
Oenococcus, Pasteuria, Pediococcus (P.), Propionibacterium, Streptococcus,
Xanthomonas and their mixtures.
The pH of the bacterial preparation according to the invention is preferably from about 4 to 10, even more preferably from about 5 to 9.
A third object of the present invention is the use of at least one strain as defined according to the first object of the present invention, as active ingredient in a probiotic-based non therapeutical product having a virucidal activity against LU505877 enveloped viruses.
A fourth object of the present invention is the use of a bacterial preparation according to the second object of the present invention, as active ingredient in a probiotic-based non therapeutical product having a virucidal activity against enveloped viruses.
According to a preferred embodiment of the invention, said enveloped viruses include influenza, human cytomegalovirus (HCMV), HIV, respiratory syncytial virus (RSV), vaccinia virus, arbovirus and human coronaviruses such as
NL63, 229E, OC43, HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2, but not limited to.
According to these uses, said product further has bactericide properties and/or cleaning properties.
A fifth object of the invention is a process for cleaning and/or preventing from contamination and/or sanitizing a surface, said process comprising at least one step of applying on said surface, at least one strain as defined according to the first object of the present invention or at least one bacterial preparation according to the second object of the present invention.
The term “cleaning” refers to the use of such a composition for cleaning surfaces, particularly inert surfaces. The term cleaning also encompasses metabolization of organic substrates (dirt) present on a surface.
The terms “preventing from contamination” means avoiding or diminishing the risk of contamination of surfaces, particularly inert surfaces, by a pathogen, in particular by pathogenic bacteria belonging to at least the families
Staphylococcaceae, Enterococcaceae, Enterobacteriaceae and Pseudomonaceae.
The term “sanitizing” refers to the fact that due to the presence of the strains according to the invention in the product, the application of such a product makes it possible to avoid and/or reduce the proliferation of pathogens on a surface and eliminate pathogens present on a surface, in particular pathogenic bacteria belonging to at least the families Staphylococcaceae, Enterococcaceae,
Enterobacteriaceae and Pseudomonaceae.
According to a preferred embodiment of the invention, said strain or said LU505877 bacterial preparation is applied on said surface in an amount of about 4.10% to 4.101 CFU/m? of surface, even more preferably in an amount of about 4.10° to 4.10%° CFU/m2.
According to a particular embodiment, the inert surface is a community surface, for example hospitals, nurseries or even accommodation establishments for the elderly, or a surface of a public or private establishment, for example kitchens.
According to the process of the invention, said strains or said bacterial preparation can be applied according to the usual procedures for cleaning and/or sanitizing and/or preventing from contamination, inert surfaces in addition to or replacing disinfection procedures known to those skilled in the art.
The process according to the invention, and therefore the use of the strains or of the bacterial preparation according to the invention, makes it possible to protect inert surfaces from contamination by enveloped-viruses pathogenic bacteria, with a lasting effect up to at least 1 day, 2 days, 3 days, 4 days or even at least 5 to 7 days.
A sixth object of the present invention is the strains as defined according to the first object of the present invention, for use as a medicament.
A seventh object of the present invention is the bacterial preparation as defined according to the second object of the present invention, for use as a medicament.
According to a particular embodiment of the present invention, said medicament is for the treatment of diseases caused by enveloped-viruses, such as influenza, human cytomegalovirus (HCMV), HIV, respiratory syncytial virus (RSV), vaccinia virus, arbovirus and human coronaviruses such as NL63, 229E, OC43,
HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2, but not limited to.
The manner in which the invention can be carried out and the advantages which result from it will become clearer from the examples of implementation which follow, given for informational and non-limiting purposes, in support of the appended figures.
BRIEF DESCRIPTION OF THE FIGURES LU505877 - Figure 1 is a graph representing virucidal activity of strains P9, P13, P14,
P17 and P18 individually or in admixture on phi6 bacteriophages comparatively to reference strains DSM 31005, DSM 361, DSM 108493 and DSM 26896. On this graph, the bacteriophage phi6 concentration (log PFU/mL) after 24 hours of contact with bacterial strains is given for each tested strain. The grey dot line represents the initial concentration of bacteriophages. The dark broken line represents the bacteriophage concentration after 24h at 30°C in PBS (negative control). - Figure 2 is a graph representing virucidal activity of strains P9, P13, P14,
P17 and P18 individually or in admixture on MS2 bacteriophages (non-enveloped bacteriophage) comparatively to a commercial Bacillus biomass. On this graph, the
MS2 concentration (log PFU/mL) after 24 hours of contact with bacterial strains is given for each tested strain. The dark broken line represents the bacteriophage concentration after 24h at 30°C in PBS. - Figure 3 is a graph representing the results of the bactericide activity of the strains P13, P14, P17 and P18 individually or in admixture comparatively to a commercial Bacillus biomass and to bleach against S. aureus. On this graph, the
S. aureus concentration (log CFU/mL) is given for each tested strain/product.
Figure 3A presents results of simultaneous co-culture respectively with S. aureus and Figure 3B presents results of a 3-hour pretreatment with the strains assessed.
The grey dot line represents the initial concentration of S. aureus. The dark broken line represents the S. aureus concentration after 24h at 30°C in PBS. - Figure 4 is a graph representing the results of the bactericide activity of the strains P13, P14, P17 and P18 individually or in admixture comparatively to a commercial Bacillus biomass and to bleach against E. hirae. On this graph, the E. hirae concentration (log CFU/mL) is given for each tested strain/product. Figure 4A presents results of simultaneous co-culture respectively with E. hirae and Figure 4B presents results of a 3-hour pre-treatment with the strains assessed. The grey dot line represents the initial concentration of S. aureus. The dark broken line represents the S. aureus concentration after 24h at 30°C in PBS. - Figure 5 is a graph representing the results of the bactericide activity of the strains P13, P14, P17 and P18 individually or in admixture comparatively to a commercial Bacillus biomass and to bleach against P. aeruginosa. On this graph, LU505877 the P. aeruginosa concentration (log CFU/mL) is given for each tested strain/product. Figure 5A presents results of simultaneous co-culture respectively with P. aeruginosa and Figure 5B presents results of a 3-hour pre-treatment with the strains assessed. The grey dot line represents the initial concentration of S. aureus. The dark broken line represents the S. aureus concentration after 24h at 30°C in PBS. - Figure 6 is a graph representing the results of the bactericide activity of the strains P13, P14, P17 and P18 individually or in admixture comparatively to a commercial Bacillus biomass and to bleach against E. coli. On this graph, the E. coli concentration (log CFU/mL) is given for each tested strain/product. Figure 6A presents results of simultaneous co-culture respectively with E. coli and Figure 6B presents results of a 3-hour pre-treatment with the strains assessed. The grey dot line represents the initial concentration of S. aureus. The dark broken line represents the S. aureus concentration after 24h at 30°C in PBS.
EXAMPLE 1: Bacterial isolation, sequencing and bioinformatic analysis of the five strains of the invention 1.1. Material and methods
Surfaces from various surfaces (kitchen swab, cat and dog skins were swabbed, and bacteria were isolated on tryptone soya agar (TSA) plate. DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, 51306) according to the manufacturer’s instructions. DNA was quantified with the Qubit® 2.0 Fluorometer (Invitrogen, Q32866) and the Qubit® dsDNA HS Assay kit (Life Technologies,
Q32851). The DNA concentration was adjusted to be within the range of three and 17 ng/L for subsequent sequencing. Libraries for the short reads sequencing were prepared using the Nextera™ DNA Flex Library Prep Kit (Illumina) and sequenced on the Miseq® platform (Illumina) achieving 250-bp paired-end reads. The quality of the raw reads was checked with FastQC ® software before and after processing the sequences with Trimmomatic ® software. The DNA extracted was also sequenced in long reads by using the Oxford Nanopore MinION Mk1c. Long reads were de novo assembled by QIAGEN CLC Genomics software and polished with short reads. The genome annotation was done by Prokka ® software. The antibiotic resistance genes were determined by CARD (Comprehensive Antibiotic LU505877
Resistance Database). Core genes shared by the five bacteria have been determined by the high-speed stand-alone pan genome pipeline Roary ® software, running with standard parameters. 1.2. Results
Genomic characterization of bacteria
The strain P9 was isolated on a kitchen swab, strains P13 and P14 on dog skin and strains P17 and P18 on cat skin.
All strains selected were considered risk group 1 and P18 was classified as
QPS (Qualified Presumption of Safety) strain. All strains were free of virulence factors, intrinsic resistance to phenicol was observed in P9 and P18. Nevertheless, multiple antibiotic resistance genes were detected in P13 and P14.
Genome characterization of bacteria for each strain is detailed in Table 1 below:
TABLE 1
Bacillus Bacillus Bacillus Bacillus Bacillus altitudinis subtilis safensis nakamurai pumilus
Genome size 3,786,196 4,080,482 4,089,512 3,095,362 3,886,394 (bp) omios| 8 | 2 | 0s | om | 1 ac (%) 3,813 4,080 5,551 3,160 3,939 mwa | 2 | om | n | ow | a wna | 81 ss | 0 |» | æ
AMR | phenicol | MDR(*) | MDR(**) | | phenicol _ . 1 intact, 2 . 3 . 1 intact, 5 07 1 intact, 2
Phages | . 2 intact . ! questionable, | . ! (*): MDR = Multi-drug resistance: aminoglycoside, cephalosporin, fluoroquinolone, lincosamide, macrolide, nucleoside, oxazolidinone, peptide antibiotic, phenicol, pleuromutilin, streptogramin and tetracycline.
(**): MDR = Multi-drug resistance: carbapenem, cephalosphorin, LU505877 cephamyicin, fluoroquinolone, glycopeptide, lincosamide, macrolide, monobactam, nucleoside, oxazolidinone, phenicol, pleuromutilin, streptogramin and tetracycline.
The five strains P9, P13, P14, P17 and P18 share 71 genes with an identity above 95 %. The consensus sequence (common sequence of the five strains) corresponds to SEQ ID n°1.
The sequences of strains P9, P13, P14, P17 and P18 correspond to SEQ ID n°2 to SEQ ID N°9 for strain P9, to SEQ ID n°10 to SEQ ID N°12 for strain P13, to
SEQ ID n°13 to SEQ ID N°17 for strain P14, to SEQ ID n°18 to SEQ ID N°90 for strain P17 and to SEQ ID n°91 for strain P18.
EXAMPLE 2: Study of the virucidal activity of the five strains of the invention 2.1. Material and methods
The virucidal activity of the five strains according to the invention was tested on bacteriophages MS2 and phi6 representing non-enveloped and enveloped viruses, respectively. First, viruses were put in contact: 3 mL of each strain P9,
P13, P14, P17 or P18, diluted in tryptone soya broth (TSB) to reach a 10° spores/mL concentration were added with 3 mL of each virus diluted in TSB to reach a 10° plaque-forming unit (PFU)/ML concentration into a 6 wells-plate. Two controls to assess the stability of bacteriophages and the growth of tested strains were made by adding 3 mL of virus and 3 mL of each strain, respectively, to 3 mL of TSB. Plates were incubated at 30°C with an agitation at 80 rpm during 24 h.
The virucidal activity of the five strains according to the invention on phi6 bacteriophages was compared to the virucidal activity of an admixture of the five strains P9, P13, P14, P17 or P18 each at a concentration of 2.10% CFU/mL in the mixture and to 4 reference strains: - Bacillus pumilus DSM 31005, denoted DSM 31005 - Bacillus pumilus DSM 361, denoted DSM 361 - Bacillus altitudinis DSM 108493, denoted DSM 108493 and - Bacillus altitudinis DSM 26896, denoted DSM 26896.
The virucidal activity of the strains P9, P14, P17 and P18 according to the invention on MS2 bacteriophages was compared to the virucidal activity of the admixture of the five strains P9, P13, P14, P17, P18 and the Bacillus biomass LU505877
BEBS2 found in the products of the brand Provilan ® sold by Probiotic Group
Luxembourg (BEBS2 biomass).
Then, each of the cultures was filtrated to remove the strains before titration of lysis plaques on E. coli K12 (bacteriophage MS2) and Pseudomonas syringae
DSM 21482 (bacteriophage phi6). 2.2. Results
The results are given on figures 1 and 2 annexed.
Figure 1 is a graph representing virucidal activity of strains P9, P13, P14,
P17 and P18 on phi6 bacteriophages comparatively to the admixture of the five strains and to reference strains DSM 31005, DSM 361, DSM 108493 and DSM 26896. On this graph, the bacteriophage phi6 concentration (log PFU/mL) is given for each tested strain. The grey dot line represents the initial concentration of bacteriophages. The dark broken line represents the bacteriophage concentration after 24h at 30°C in PBS (negative control).
Figure 2 is a graph representing virucidal activity of strains P9, P13, P14,
P17 and P18 on MS2 bacteriophages comparatively to BEBS2 biomass and to the admixture of the five strains. On this graph, the MS2 concentration (log PFU/mL) after 24 hours of contact with bacterial strains is given for each tested strain. The dark broken line represents the bacteriophage concentration after 24h at 30°C in
PBS.
These results show that the admixture of the five strains of the invention, and the strains P9, P14, P17 and P18 alone, don't have virucidal activity on the non-enveloped bacteriophage MS2 (Fig. 2). On the contrary, results presented on
Fig. 1 show that the five strains of the invention have a high virucidal activity on the enveloped bacteriophage phi6.
EXAMPLE 3: Study of the enzymatic activity of the five strains of the invention 3.1. Material and methods
The enzymatic activity of the five strains P9, P13, P14, P17 and P18 was evaluated on different media:
i) Lipid degradation: LUS05877
Tributyrin agar medium had the following composition: tributyrin 10 g.L*, yeast extract 3 g.L*, peptone 5 g.L*, agar 15 g.L*. ii) Casein degradation
Skim milk agar medium has the following composition: skim milk 28 g.L*, casein enzymatic hydrolysate 5 g.L!, yeast extract 2.5 g.L!, glucose 1 mL.L*, agar 15 g.L*. iii) Lecithinase activity:
Egg yolk agar medium had the following composition: pancreatic digest of casein 10 g.L*, meat extract 3 g.L*, yeast extract 1 g.L*, NaCl 5 g.L*, egg yolk emulsion 100 mL.L?, agar 15 g.L4. iv) Starch hydrolysis:
Starch agar medium has the following composition: peptone 5 g.L!, starch 10 g.L}, agar 10 g.L*. v) Haemolysis (ThermoFisher):
Columbia sheep blood agar medium has the following composition:
Columbia agar + 7% sheep blood. vi) Urease activity:
Urea agar medium has the following composition: urea agar base 24 g.L*, 40% urea solution 50 mL.L*. vii) Cellulolytic activity:
Carboxymethylcellulose agar medium had the following composition: carboxymethylcellulose 26 g.L!, yeast extract 1 g.L*, agar 15 g.L*).
Each strain was resuspended in PBS to obtain an OD600nm (optical density measured at a wavelength of 600 nm in 1 cm light path) between 0.5 and 0.6 and 10 pL were dropped in the middle of a Petri dish. Plates were incubated one week at 20°C. The starch hydrolysis and cellulolytic activity were revealed with lugol and congo red/acridine orange, respectively. The list of enzymatic activities of the five strains according to the invention was completed by API ZYM® (Biomérieux 25200) according to the manufacturer recommendations: alkaline phosphatase, esterase (C4), esterase lipase (C8), lipase (C14), leucine arylamidase, valine arylamidase, cystine arylamidase, trypsin, a-chymotrypsin, acid phosphatase, LU505877 naphthol-AS-BI-phosphohydrolase, a-galactosidase, B-galactosidase, B- glucuronidase, a-glucosidase, B-glucosidase, N-acetyl-B-glucosaminidase, a- mannosidase, and a-fucosidase. 3.2. Results
The results are reported in table 2 below in which the sign “+” means that the strain presents the indicated enzymatic activity while the sign *-" means that the strain does not present the indicated enzymatic activity:
TABLE 2 strain
Hæemoiysis | = | + | + | + | + ) Amylase | - | + | + | + | - ) Uipase | + | + | + | + | =) eae |--- beet | RP
Leucine eryiamidase | + | - | qe | +
Vaineamamiæe | - | - | - | - | -
Gséimeavemuæse | + | - | - | - ese | | T1 T1 TT) aowmowypsne | + | - | 0 + | + @-galactosidase | - | + | + | = | -
BrGalactosidase | + | = | + | = | +
Bralucuronidase | - | + | - | - | - ogucosidase | - | + | + | + | -
Br@lucosidase | + | + | + | = | + [TOF
Nracetyl-B-glucosidase | - | - | - | - | - @-mamnosidase | + | = | - | - | - @efucosidase | - | - | - | - | -
These results show that the five strains demonstrate interesting enzymatic activities allowing the cleaning of various dirt: milk, blood, starch or cellulose.
EXAMPLE 4: Study of the bactericidal activity of the five strains of the invention 4.1. Material and methods
The biocidal activity of the five strains according to the invention, individually and in admixture was tested against Enterococcus hirae (ATCC10541),
Escherichia coli (NCTC10536,) Staphylococcus aureus (ATCC6538), and
Pseudomonas aeruginosa (ATCC15442) was quantified by viability qPCR with primers listed in the following Table 3:
TABLE 3 (SEQ ID n°7) (SEQ ID N°8) (SEQ ID N°9) (SEQ ID N°10) (SEQ ID N°11) (SEQ ID N°12) aeruginosa (SEQ ID N°13) (SEQ ID N°14) (SEQ ID N°15) (SEQ ID N°16)
The viability qPCR can only detect DNA from live cells thanks to a pre- treatment with a photoreactive membrane-impermeant DNA binding dye (PMAxx ®, Biotium). Because the dye is cell membrane-impermeable, when a sample containing both live and dead bacteria is treated, only dead bacteria with compromised cell membranes are susceptible to DNA modification. The dye intercalates into dsDNA and forms a covalent linkage upon exposure to intense visible light, inhibits PCR amplification.
1 mL of target pathogen at 107 CFU/mL were cocultured with 1 mL of strain LU505877 (P9, P13, P14, P17 and P18 individually or in admixture) (107 spores/mL) in 8 mL liquid culture (TSB), meaning an initial concentration of both target pathogens and strains at 10° CFU/ML or spores/mL, respectively. Each co-culture was incubated for 24 hours at 30°C (110 rpm). To test the preventive action of the strains according to the invention, the culture was pre-treating with Bacillus strains three hours before adding the pathogen. After the co-culture, samples were treated with the PMAxx® dye, DNA was extracted (Qiagen QIAamp Mini Kit, 51306), and qPCR were performed. Bleach treatment was used as positive control for the biocide and culture in PBS is used as negative control showing the normal growth of pathogen.
All experiments were done in triplicate. Biocide activity of the strains P9, P13, P14,
P17 and P18 individually and in admixture were quantified by viability gPCR and compared with biocide activity of biomass BEBS2 and bleach. 4.2. Results
The results are given on figures 3 to 6 annexed.
On these figures, the concentration of the target pathogen (in log CFU/mL) is given for each tested coculture. Strains assessed are P9, P13, P14, P17, P18 independently and in admixture, in comparison with biomass BEBS2 and with bleach as positive control for biocide. Figures 3A, 4A, 5A and 6A present results of simultaneous co-culture respectively with S. aureus, E. hirae, P. aeruginosa and
E. coli while figures 3B, 4B, 5B and 6B present results of the 3-hour pre-treatment with the strains assessed. The grey dot line represents the initial concentration of the target pathogen and the dark broken line represents the S. aureus concentration after 24h at 30°C in PBS.
The presence in co-culture of the strains P9 to P18 (alone or in admixture) significantly decreases the number of S. aureus. Strains P9, P13, P14 and P17 reduce the S. aureus concentration by more than 5 log (minimal reduction required to be a biocide according to EU standards). In case of a pre-treatment with strains 3 hours before the contamination with S. aureus, the treatment also significantly reduces the pathogen growth. The presence of the strains according to the invention reduces the population of S. aureus in comparison to a pathogen monoculture but also in comparison to the initial contamination of pathogen.
Concerning the other pathogens, the presence of the strains according to the invention does not allow to reduce the pathogen concentration above the initial contamination except in the case of a strain pre-treatment three hours before the LU505877
E. hirae contamination.
Claims (16)
1. Isolated strains of spore-forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said strains are selected from Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian Coordinated Collections of Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P- 33408 at the BCCM on December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P-33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on December 8, 2023.
2. Isolated strains according to claim 1, wherein said strains have a consensus nucleotidic sequence SEQ ID N°1 or a nucleotidic sequence having at least 95% of identity with said nucleotidic sequence SEQ ID N°1.
3. A bacterial preparation comprising a culture of at least one strain of spore- forming bacteria of the Bacillus species having a virucidal activity against enveloped viruses, wherein said at least one strain is selected in the group consisting of the five following strains: Bacillus altitudinis (P9), deposited under the number LMG P-33406 at the Belgian Coordinated Collections of Microorganisms (BCCM) on December 8, 2023, Bacillus subtilis (P13), deposited under the number LMG P-33407 at the BCCM on December 8, 2023, Bacillus pumilus (P14), deposited under the number LMG P-33408 at the BCCM on December 8, 2023, Bacillus nakamurai (P17), deposited under the number LMG P-33409 at the BCCM on December 8, 2023, and Bacillus safensis (P18), deposited under the number LMG P-33410 at the BCCM on December 8, 2023.
4. The bacterial preparation according to claim 3, wherein said preparation is free from any surface-active agent.
5. The bacterial preparation according to claim 3 or 4, wherein said preparation comprises said five strains.
6. The bacterial preparation according to any one of claims 3 to 5, wherein said strains are in the form of spores and/or of vegetative cells and/or of cells in the transitional sporulation phase.
7. The bacterial preparation according to claim 6, wherein said strains are in LU505877 the form of spores and further wherein said spores are suspended in an aqueous medium.
8. The bacterial preparation according to any one of claims 3 to 7, wherein the concentration of said strain is from 10? CFU/mL to 10! CFU/mL.
9. Use of at least one strain as defined in claim 1 or 2, as active ingredient in a probiotic-based non-therapeutical product having a virucidal activity against enveloped viruses.
10. Use of a bacterial preparation according to any one of claims 3 to 8, as active ingredient in a probiotic-based non-therapeutical product having a virucidal activity against enveloped viruses.
11. Use according to claim 9 or 10, wherein said product further has bactericide properties and/or cleaning properties.
12. A process for cleaning and/or preventing from contamination and/or sanitizing a surface, said process comprising at least one step of applying on said surface, at least one strain as defined in claim 1 or 2 or at least one bacterial preparation as defined in any one of claims 3 to 8.
13. The process according to claim 12, wherein said strain or said bacterial preparation is applied on said surface in an amount of 4.10° to 4.10% CFU/m? of surface.
14. The strains as defined in claim 1 or 2, for use as a medicament.
15. The bacterial preparation as defined in any one of claims 3 to 8, for use as a medicament.
16. The strain for use according to claim 14 or the bacterial preparation for use according to claim 15, wherein said medicament is for the treatment of diseases caused by enveloped-viruses.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU505877A LU505877B1 (en) | 2023-12-21 | 2023-12-21 | Bacillus-based product having virucide activity against enveloped virus and applications thereof |
| PCT/EP2024/088231 WO2025133336A1 (en) | 2023-12-21 | 2024-12-20 | Bacillus-based product having virucide activity against enveloped virus and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU505877A LU505877B1 (en) | 2023-12-21 | 2023-12-21 | Bacillus-based product having virucide activity against enveloped virus and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU505877B1 true LU505877B1 (en) | 2025-06-24 |
Family
ID=89474477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU505877A LU505877B1 (en) | 2023-12-21 | 2023-12-21 | Bacillus-based product having virucide activity against enveloped virus and applications thereof |
Country Status (2)
| Country | Link |
|---|---|
| LU (1) | LU505877B1 (en) |
| WO (1) | WO2025133336A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016170479A1 (en) | 2015-04-22 | 2016-10-27 | Copma S.C.A.R.L. | Product for cleaning, sanitizing and hygienization |
| WO2021243324A1 (en) | 2020-05-29 | 2021-12-02 | Novozymes A/S | Microbial cleaning compositions |
-
2023
- 2023-12-21 LU LU505877A patent/LU505877B1/en active IP Right Grant
-
2024
- 2024-12-20 WO PCT/EP2024/088231 patent/WO2025133336A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016170479A1 (en) | 2015-04-22 | 2016-10-27 | Copma S.C.A.R.L. | Product for cleaning, sanitizing and hygienization |
| WO2021243324A1 (en) | 2020-05-29 | 2021-12-02 | Novozymes A/S | Microbial cleaning compositions |
Non-Patent Citations (8)
| Title |
|---|
| ABEDNE REUBEN N ET AL: "Antibacterial activity of soil-isolated Bacillus altitudinis/ pumilus complex against methicillin-resistant Staphylococcus aureus from Mwanza, Tanzania", AFRICAN JOURNAL OF LABORATORY MEDICINE, 18 July 2023 (2023-07-18), pages 1 - 5, XP093180755, ISSN: 2225-2010, DOI: https://doi.org/10.4102/ajlm.v12i1.2167 * |
| ALBERTA VANDINI ET AL: "Hard Surface Biocontrol in Hospitals Using Microbial-Based Cleaning Products", PLOS ONE, vol. 9, no. 9, 26 September 2014 (2014-09-26), pages e108598, XP055570303, DOI: 10.1371/journal.pone.0108598 * |
| CROVELLA SERGIO ET AL: "Surfactin Bacterial Antiviral Lipopeptide Blocks In Vitro Replication of SARS-CoV-2", APPLIED MICROBIOLOGY, vol. 2, no. 3, 9 September 2022 (2022-09-09), pages 680 - 687, XP093180610, ISSN: 2673-8007, DOI: 10.3390/applmicrobiol2030052 * |
| D'ACCOLTI MARIA ET AL: "Potential of an Eco-Sustainable Probiotic-Cleaning Formulation in Reducing Infectivity of Enveloped Viruses", VIRUSES, vol. 13, no. 11, 4 November 2021 (2021-11-04), CH, pages 2227, XP093177455, ISSN: 1999-4915, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617880/pdf/nihpp-rs4169007v1.pdf> DOI: 10.3390/v13112227 * |
| LIU JIN ET AL: "Surfactin effectively inhibitsStaphylococcus aureus adhesion and biofilm formation on surfaces", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 103, no. 11, 22 April 2019 (2019-04-22), pages 4565 - 4574, XP036776485, ISSN: 0175-7598, [retrieved on 20190422], DOI: 10.1007/S00253-019-09808-W * |
| LIU SHU ET AL: "Four Novel Leaderless Bacteriocins, Bacin A1, A2, A3, and A4 Exhibit Potent Antimicrobial and Antibiofilm Activities against Methicillin-Resistant Staphylococcus aureus", MICROBIOLOGY SPECTRUM, vol. 10, no. 5, 26 October 2022 (2022-10-26), US, XP093177785, ISSN: 2165-0497, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602277/pdf/nihpp-rs4169007v1.pdf> DOI: 10.1128/spectrum.00945-22 * |
| SZMIGIEL I ET AL: "The influence of Bacillus subtilis 87Y isolated from Eisenia fetida on the growth of pathogenic and probiotic microorganisms", BIOMASS CONVERSION AND BIOREFINERY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 11, no. 2, 28 December 2019 (2019-12-28), pages 601 - 608, XP037612827, ISSN: 2190-6815, [retrieved on 20191228], DOI: 10.1007/S13399-019-00582-3 * |
| WANG YING ET AL: "A novel trehalosamine isolated from Bacillus amyloliquefaciens and its antibacterial activities", AMB EXPRESS, vol. 10, no. 1, 1 December 2020 (2020-12-01), DE, XP093177802, ISSN: 2191-0855, Retrieved from the Internet <URL:https://amb-express.springeropen.com/counter/pdf/10.1186/s13568-019-0943-x.pdf> DOI: 10.1186/s13568-019-0943-x * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025133336A1 (en) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Romanenko et al. | Isolation, phylogenetic analysis and screening of marine mollusc-associated bacteria for antimicrobial, hemolytic and surface activities | |
| Furukawa et al. | Sugar fatty acid esters inhibit biofilm formation by food-borne pathogenic bacteria | |
| Li et al. | Control of Listeria monocytogenes biofilm by paenibacterin, a natural antimicrobial lipopeptide | |
| EP2852402B1 (en) | Therapeutic for treating clostridium difficile infection | |
| Bai et al. | Insight into the effect of quinic acid on biofilm formed by Staphylococcus aureus | |
| Ripolles-Avila et al. | New approach for the removal of mature biofilms formed by wild strains of Listeria monocytogenes isolated from food contact surfaces in an Iberian pig processing plant | |
| CN107849518A (en) | The preparation for natural plant protecting and plant enhancing is developed from the raw bacillus of new plant endogenetic bacteria rice of rice rhizosphere separation and using it | |
| Ripolles‐Avila et al. | Removal of Salmonella enterica serovar Typhimurium and Cronobacter sakazakii biofilms from food contact surfaces through enzymatic catalysis | |
| Solis-Velazquez et al. | Nosocomial pathogen biofilms on biomaterials: Different growth medium conditions and components of biofilms produced in vitro | |
| Yuan et al. | Interspecies interactions in dual-species biofilms formed by psychrotrophic bacteria and the tolerance of sessile communities to disinfectants | |
| US20170064965A1 (en) | Antimicrobial peptides derived from phage of acinetobacter baumannii and use thereof | |
| US20090104172A1 (en) | Methods for killing spores and disinfecting or sterilizing devices | |
| US20220195347A1 (en) | Composition | |
| Shangguan et al. | Anti‐biofilm potential of kefir‐derived Lactobacillus paracasei L10 against Vibrio parahaemolyticus | |
| Wang et al. | Dynamic tracing of bacterial community distribution and biofilm control of dominant species in milk powder processing | |
| Mnif et al. | Enzyme-based strategy to eradicate monospecies Macrococcus caseolyticus biofilm contamination in dairy industries | |
| Schwab et al. | Alternative sigma factor σB is not essential for Listeria monocytogenes surface attachment | |
| Mazaheri et al. | Removal of Listeria monocytogenes biofilms on stainless steel surfaces through conventional and alternative cleaning solutions | |
| US20090305387A1 (en) | Compositions and methods for cleaning surfaces | |
| LU505877B1 (en) | Bacillus-based product having virucide activity against enveloped virus and applications thereof | |
| EP1283010A1 (en) | Compositions based on bacterial complexes and their application for preventing nosocomial infections | |
| FR3118058A1 (en) | STRAIN OF BACILLUS PUMILUS PRESENTING A STRONG ANTAGONISM TOWARDS SURFACE PATHOGENS | |
| Anand et al. | The emergence of predominance in the constitutive microflora of dairy membrane biofilms | |
| Zinn et al. | How Effective Are Cleaners With “Effective Microorganisms”? | |
| Bonhi et al. | A comparative profile of bactericidal action of a partially purified bacteriocin from lactic acid bacteria with antibiotics. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20250624 |